Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.

Inclusion Criteria: • Presence of Rheumatoid Arthritis classified by ACR 2010 revisedcriteria for at least 3 months •Disease activity defined by ≥6 tender joints out of 68 and ≥ 6 swollen joints out of 66 at baseline and with: Either Anti-CCP antibodies positive ORRheumatoid Factor positive AND WITH Either hsCRP ≥ 10 mg/L OR ESR ≥28 mm/1st hr •Intake ofat least one anti-TNF-α agent such as etanercept, adalimumab, infliximab, certolizumab orgolimumab for at least 3 months before entering the study and to have experienced aninadequate response to treatment or to have been intolerant to at least one administration

Exclusion Criteria:

• Current RA functional status class IV according to the ACR 1991 revised criteria •Previous use of secukinumab or other biologic drug directly targeting IL-17 or IL-17receptor and/or any history of hypersensitivity to secukinumab or its excipient or todrugs of similar chemical classes. Other protocol-defined inclusion/exclusion criteriamay apply